FDA updates warning labels on gadolinium contrast

The U.S. Food and Drug Administration today announced that it is updating the warning labels required on three gadolinium-based MRI contrast agents sold in the U.S. due to the risk of nephrogenic systemic fibrosis.

Click here to read the rest of the article.

Page 1 of 611
Next Page